903556-72-9 Usage
Uses
Used in Pharmaceutical Industry:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as a building block for the synthesis of various drugs and pharmaceuticals due to its unique structure and diverse range of biological activities.
Used in Antioxidant Applications:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as an antioxidant agent for its ability to combat oxidative stress, which is a common factor in many diseases.
Used in Anti-inflammatory Applications:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as an anti-inflammatory agent for its potential to reduce inflammation, which is a key component in many chronic conditions.
Used in Antitumor Applications:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as an anti-tumor agent for its potential to inhibit tumor growth and progression, making it a candidate for cancer treatment.
Used in Neurological Disorders Treatment:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as a potential therapeutic agent in the treatment of neurological disorders due to its biological activities that may help alleviate symptoms and improve patient outcomes.
Used in Cancer Treatment:
2,2-diMethyl-2,3-dihydrobenzofuran-5-carbonitrile is used as a potential therapeutic agent in cancer treatment for its potential to exhibit anti-tumor properties and contribute to the development of new cancer therapies.
Check Digit Verification of cas no
The CAS Registry Mumber 903556-72-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,3,5,5 and 6 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 903556-72:
(8*9)+(7*0)+(6*3)+(5*5)+(4*5)+(3*6)+(2*7)+(1*2)=169
169 % 10 = 9
So 903556-72-9 is a valid CAS Registry Number.
903556-72-9Relevant academic research and scientific papers
Multicyclic bis-amide MMP inhibitors
-
Page/Page column 96, (2008/06/13)
The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
